Investor Presentaiton
Investor presentation
First three months of 2017
Slide 62
Key Novo Nordisk diabetes care products remain broadly
available in the US
Value market shares of key
Novo Nordisk products in the US
Value market
share
VictozaⓇ
TresibaⓇ
NovoLogⓇ
% unrestricted market access of key
Novo Nordisk products in the US
VictozaⓇ
TresibaⓇ
NovoLogⓇ
LevemirⓇ
80%
60%
40%
20%
0%
Jan
2014
Source: IMS NSP February 2017;
LevemirⓇ
Unrestricted
Market access
100%
80%
60%
40%
20%
0%
Feb
2017
Note: Market shares: NovoLogⓇ: share of rapid acting insulin segment; LevemirⓇ: share of basal insulin
segment; TresibaⓇ share of basal insulin segment; VictozaⓇ: share of GLP-1 segment
changing
diabetes
Jan
2014
Source FingerTip Formulary bridge/ January 2017 Nomenclature and Xponent PlanTrak
using week-ending 2/3/2017; only considers bridged volume; excludes cash and mail
order data;
Note: Unrestricted access excludes prior authorisation, step edits and other restrictions
LevemirⓇ access based on FlexTouch® Pen; NovoLogⓇ access based on FlexPenⓇ; only
considers bridged volume; TresibeⓇ launched in January 2016
Jan
2017
novo nordiskView entire presentation